Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1997 1
2003 3
2004 2
2006 7
2007 1
2008 3
2009 3
2010 3
2011 3
2012 5
2013 6
2014 11
2015 6
2016 7
2017 13
2018 11
2019 14
2020 14
2021 10
2022 12
2023 9
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

131 results

Results by year

Filters applied: . Clear all
The following terms were ignored: %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %, %
The following terms were not found in PubMed: 2Fgenetics, 5Bmajr, 2Fetiology, 5Bmajr, jsubsetk, 5Btext, jsubsetn, 5Btext, jsubsetaim, 5Btext, 5Bmh, 5Bla
Page 1
Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, Double-Blind Phase 3 Trial in Early Alzheimer's Disease.
Cohen S, van Dyck CH, Gee M, Doherty T, Kanekiyo M, Dhadda S, Li D, Hersch S, Irizarry M, Kramer LD. Cohen S, et al. J Prev Alzheimers Dis. 2023;10(4):771-777. doi: 10.14283/jpad.2023.123. J Prev Alzheimers Dis. 2023. PMID: 37874099 Clinical Trial.
In phase 3 development, lecanemab has been shown to reduce markers of amyloid in early Alzheimer's disease and reduce decline on clinical endpoints of cognition and function at 18 months. ...DESIGN: Clarity AD was an 18-month, multi-center, double-blind, phase 3 tri …
In phase 3 development, lecanemab has been shown to reduce markers of amyloid in early Alzheimer's disease and reduce decline …
Aerobic and strength training exercise programme for cognitive impairment in people with mild to moderate dementia: the DAPA RCT.
Lamb SE, Mistry D, Alleyne S, Atherton N, Brown D, Copsey B, Dosanjh S, Finnegan S, Fordham B, Griffiths F, Hennings S, Khan I, Khan K, Lall R, Lyle S, Nichols V, Petrou S, Zeh P, Sheehan B. Lamb SE, et al. Health Technol Assess. 2018 May;22(28):1-202. doi: 10.3310/hta22280. Health Technol Assess. 2018. PMID: 29848412 Free PMC article. Clinical Trial.
The comparator was usual practice. MAIN OUTCOME MEASURES: The primary outcome was the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog). ...Carer outcomes were HRQoL (Quality of Life in Alzheimer's Disease) (as measured using the EQ- …
The comparator was usual practice. MAIN OUTCOME MEASURES: The primary outcome was the Alzheimer's Disease Assessment Scale - C …
Effect of a multicomponent exercise programme (VIVIFRAIL) on functional capacity in frail community elders with cognitive decline: study protocol for a randomized multicentre control trial.
Casas-Herrero A, Anton-Rodrigo I, Zambom-Ferraresi F, Sáez de Asteasu ML, Martinez-Velilla N, Elexpuru-Estomba J, Marin-Epelde I, Ramon-Espinoza F, Petidier-Torregrosa R, Sanchez-Sanchez JL, Ibañez B, Izquierdo M. Casas-Herrero A, et al. Trials. 2019 Jun 17;20(1):362. doi: 10.1186/s13063-019-3426-0. Trials. 2019. PMID: 31208471 Free PMC article.
Additionally, very recent research has shown that, despite its limitations, physical exercise is associated with a reduced risk of dementia, Alzheimer disease or mild cognitive decline. Nevertheless, the effect of physical exercise as a systematic, structured and re …
Additionally, very recent research has shown that, despite its limitations, physical exercise is associated with a reduced risk of dementia, …
The impact of individual Cognitive Stimulation Therapy (iCST) on cognition, quality of life, caregiver health, and family relationships in dementia: A randomised controlled trial.
Orrell M, Yates L, Leung P, Kang S, Hoare Z, Whitaker C, Burns A, Knapp M, Leroi I, Moniz-Cook E, Pearson S, Simpson S, Spector A, Roberts S, Russell I, de Waal H, Woods RT, Orgeta V. Orrell M, et al. PLoS Med. 2017 Mar 28;14(3):e1002269. doi: 10.1371/journal.pmed.1002269. eCollection 2017 Mar. PLoS Med. 2017. PMID: 28350796 Free PMC article. Clinical Trial.
Caregivers delivering iCST received training and support from an unblind researcher. Primary outcomes were cognition (Alzheimer's Disease Assessment Scale-cognitive [ADAS-Cog]) and self-reported QoL (Quality of Life Alzheimer's Disease [QoL-AD]) for th …
Caregivers delivering iCST received training and support from an unblind researcher. Primary outcomes were cognition (Alzheimer's …
Caregiver Burden and Quality of Life Across Alzheimer's Disease Severity Stages.
van Hezik-Wester VJ, Handels RLH, Wolfs CAG, Kanters TA. van Hezik-Wester VJ, et al. Alzheimer Dis Assoc Disord. 2023 Apr-Jun 01;37(2):134-141. doi: 10.1097/WAD.0000000000000558. Epub 2023 May 8. Alzheimer Dis Assoc Disord. 2023. PMID: 37253123
Proxy-rated utility scores for PwADs decreased with increasing disease severity (0.455, 0.314, and 0.212 for mild, moderate, and severe AD, respectively). ...There was no difference in informal care time, societal costs, CarerQol scores, and caregiver EQ-5D-5L score …
Proxy-rated utility scores for PwADs decreased with increasing disease severity (0.455, 0.314, and 0.212 for mild, moderate, and seve …
Attitudes toward Alzheimer's disease and dementia caregiving and health outcomes: Racial and ethnic differences.
Im EO, Kim HJ, Kim SY, Yau YC, Brewster GS, Chee W. Im EO, et al. Geriatr Nurs. 2022 Nov-Dec;48:296-302. doi: 10.1016/j.gerinurse.2022.10.018. Epub 2022 Nov 3. Geriatr Nurs. 2022. PMID: 36335856 Free PMC article.
This study aimed to explore racial/ethnic differences in the attitudes toward Alzheimer's Disease (AD) and dementia caregiving among midlife women who were family caregivers of persons living with AD (MWPLAD) in the U.S. and examine the associations of the attitudes …
This study aimed to explore racial/ethnic differences in the attitudes toward Alzheimer's Disease (AD) and dementia caregiving …
Acceptability and Validity of the EQ-5D in Patients Living With Dementia.
Michalowsky B, Xie F, Kohlmann T, Gräske J, Wübbeler M, Thyrian JR, Hoffmann W. Michalowsky B, et al. Value Health. 2020 Jun;23(6):760-767. doi: 10.1016/j.jval.2020.01.022. Epub 2020 May 22. Value Health. 2020. PMID: 32540234 Free article.
OBJECTIVES: To assess the acceptability and validity of the 3 levels of the EQ-5D (EQ-5D-3L) compared with the Quality of Life in Alzheimer's Diseases (QoL-AD) in patients living with dementia. ...The convergent validity was assessed using Spearman's correlat …
OBJECTIVES: To assess the acceptability and validity of the 3 levels of the EQ-5D (EQ-5D-3L) compared with the Quality of Life …
Systematic Review of Cost-Utility Analyses That Have Included Carer and Family Member Health-Related Quality of Life.
Scope A, Bhadhuri A, Pennington B. Scope A, et al. Value Health. 2022 Sep;25(9):1644-1653. doi: 10.1016/j.jval.2022.02.008. Epub 2022 Mar 24. Value Health. 2022. PMID: 35339379 Free article. Review.
CUAs examined 13 different conditions including 15 CUAs on vaccination, 5 on Alzheimer's disease, 2 on Parkinson's disease, 3 on dementia, and 2 on terminal illness. The EQ-5D was the most commonly used measure of family member health. Generally, inclu …
CUAs examined 13 different conditions including 15 CUAs on vaccination, 5 on Alzheimer's disease, 2 on Parkinson's disease …
Design, Synthesis, and Biological Evaluation of Piperazine and N-Benzylpiperidine Hybrids of 5-Phenyl-1,3,4-oxadiazol-2-thiol as Potential Multitargeted Ligands for Alzheimer's Disease Therapy.
Waiker DK, Verma A, Akhilesh, A GT, Singh N, Roy A, Dilnashin H, Tiwari V, Trigun SK, Singh SP, Krishnamurthy S, Lama P, Davisson VJ, Shrivastava SK. Waiker DK, et al. ACS Chem Neurosci. 2023 Jun 7;14(11):2217-2242. doi: 10.1021/acschemneuro.3c00245. Epub 2023 May 22. ACS Chem Neurosci. 2023. PMID: 37216500
Our present work demonstrates the successful design and synthesis of a new class of compounds based upon a multitargeted directed ligand design approach to discover new agents for use in Alzheimer's disease (AD). All the compounds were tested for their in vitro inhi …
Our present work demonstrates the successful design and synthesis of a new class of compounds based upon a multitargeted directed ligand des …
Disutility of illness for caregivers and families: a systematic review of the literature.
Wittenberg E, Prosser LA. Wittenberg E, et al. Pharmacoeconomics. 2013 Jun;31(6):489-500. doi: 10.1007/s40273-013-0040-y. Pharmacoeconomics. 2013. PMID: 23572441 Free PMC article. Review.
Generic (indirect) utility instruments were primarily used to measure spillover, including the EQ-5D, QWB, and HUI (n = 13), though two studies used modified versions of the time trade-off technique. Illnesses studied included childhood disorders (e.g., spina bifida, conge …
Generic (indirect) utility instruments were primarily used to measure spillover, including the EQ-5D, QWB, and HUI (n = 13), though t …
131 results